Trials No Longer Recruiting

The following MDS clinical trials are no longer open to recruitment in the UK.

Clinical trials are expected to recruit patients for a finite period of time. Each trial has an expected recruitment target, i.e. a specific number of patients needed to participate in the trial in order for the results of the trial to be meaningful and answer all of the proposed questions. Once this target is achieved, the trial is closed to recruitment and the data obtained from the trial is analysed and interpreted. It can take several months for this analysis to be completed. The final results are often published in international journals and/or presented at a scientific meeting.

Please visit the following page for Currently Open MDS Clinical Trials.

If you'd like more information about what is a clinical trial and how it is conducted, please go to this section

Learn more about the latest MDS research

MDS Trials No Longer Recruiting

MONOCLE

  1. SUBTYPE OF MDS: Chronic myelomonocytc leukaemia (CMML)
  2. SEVERITY OF MDS: CMML specific prognostic score (CPSS) Intermediate-2 or high risk
  3. NAME OF DRUG: Tefinostat, a histone deacetylase inhibitor that targets monocytes. Tefinostat will be administered orally on a continuous basis for at least 6 cycles each 28 days in length.
Read full story

CATAPULT

  1. SUB-TYPE OF MDS: MDS with 10% bone marrow blasts and also Acute Myeloid Leukaemia
  2. SEVERITY OF MDS: Intermediate – 2 or High Risk
  3. NAME OF DRUG: Gene modified WT1 (Wilms’ Tumor 1) TCR therapy – Patient’s white blood cells (T cells) will be modified by transferring a gene which enables them to make a new T cell receptor (TCR) that can recognize fragments of a protein called WT1 which is present at abnormally high levels on the surface of myelodysplastic and leukaemic cells.
Read full story

REDDS

  1. SUB-TYPE OF MDS: All MDS patients who are transfusion dependant
  2. SEVERITY OF MDS: All
  3. INVESTIGATIONAL INTERVENTION: Blood transfusion support
Read full story

FIGARO

  1. SUB-TYPE OF MDS: Patients with AML and MDS undergoing reduced intensity conditioning (RIC) allogeneic stem cell transplantation (SCT)
  2. SEVERITY OF MDS: Intermediate – 2 or High Risk
  3. NAME OF DRUG: Novel conditioning regimen: fludarabine/cytarabine/amsacrine/busulphan/ATG (FLAMSA-BU)
Read full story

MEDALIST (HAEM 5606)

  1. SUB-TYPE OF MDS: IPSS-R and ring sideroblasts
  2. SEVERITY OF MDS: Low or Intermediate
  3. NAME OF DRUG: Luspatercept, a protein found to promote red blood cell formation by regulating the growth of red blood cells during the late-stage of their development. It works differently to erythropoietin.
Read full story

Durvalumab in Previously Untreated Patients

  1. SUB-TYPE OF MDS: Higher risk MDS and also elderly patients (age ≥ 65 years) with Acute Myeloid Leukaemia
  2. SEVERITY OF MDS: Intermediate –2 or High Risk
  3. NAME OF DRUG: Subcutaneous Azacitidine and Durvalumab, which activates the immune system to have a response against tumor cells.
Read full story

CAMELLIA

  1. SUB-TYPE OF MDS: Patients with Acute Myeloid Leukemia that has returned after a period of improvement (relapsed) or have not responded to previous treatment (refractory).
  2. SEVERITY OF MDS: Higher Risk
  3. NAME OF DRUG: Anti-CD47 monoclonal antibody, Hu5F9-G4 (target therapy that blocks the growth of cancer cells)
Read full story
Free donations by shopping